Navigation Links
Cardio3 BioSciences Publishes the Science Basis for C-Cure(R) in JACC
Date:8/16/2010

Mayo approach as a "boot camp" for stem cells and that the study "...provides the first convincing evidence that MSCs, at least in vitro, can in fact become functional cardiomyocytes (heart cells)..."

Cardio3 BioSciences has advanced the development of this technology with the recent conclusion of a Phase II clinical trial that recruited 45 heart failure patients in Europe. The Company recently announced that its lead compound C-Cure had an excellent safety profile and observed positive trends in both physiological and clinical heart function, as was anticipated from the animal model data published in JACC. C-Cure's unique repair action on heart muscle is projected to yield clinical benefits in a Phase III trial setting.

Dr Christian Homsy, CEO of Cardio3 BioSciences said: "Publication of this research in a journal as prestigious as JACC highlights the quality of the science underlying our lead product. This trans-Atlantic effort involving leading edge science in both the US and Belgium served to dramatically increase the potency of human stem cells to repair heart tissue and provides the basis for C-Cure, a therapy that could revolutionize the treatment of this devastating disease.

"Based on this world-class science and the insights and confidence we have gained from our first clinical trial, we are now finalising the design of our pivotal clinical program for C-Cure and look forward to continuing to steps needed to bring this much needed treatment to patients."

The research was supported by the National Institutes of Health, the American Heart Association, the Marriott Heart Disease Research Program, Cardio3 BioSciences, the Ted Nash Long Life Foundation, the Ralph Wilson Medical Research Foundation, the Mayo Clinic General Mills Clinician-Investigator Fellowship, and Mayo Clinic.

The paper's authors include Atta Behfar, M.D., Ph.D., Satsuki Yamada, M.D., Ph.D., Ruben Crespo-Diaz, Jonathan Nesbitt, Lois Rowe,

SOURCE Cardio3 BioSciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Cardio3 BioSciences Reports Positive Three-Month Data From its Clinical Trial of C-Cure(R) in Heart Failure
2. Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure
3. Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress
4. Signum Biosciences Names Braham Shroot as Chief Executive Officer
5. YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study
6. CORRECTED: Ampio Pharmaceuticals Announces Completion of Negotiations for Acquisition of DMI BioSciences, Inc.
7. Ambit Biosciences Announces Transition in Company Leadership
8. Sangamo BioSciences Announces Second Quarter 2010 Conference Call and Webcast
9. Calithera Biosciences Closes $40 Million in Series A Financing
10. MD Biosciences Offers Occlusion-induced Myocardial Infarct Model for Investigating the Cardio-protection of a Drug Treatment in the Event of Ischemia/reperfusion Injury
11. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... August 19, 2014 Robin Williams’ passing ... can take on an individual. Symptoms range from ... expression, problems swallowing and severe depression. Parkinson’s disease ... off of dopamine producing neurons of the brain. ... disease that slowly and progressively gets worse, they look ...
(Date:8/19/2014)... 2014 Research and Markets ... "Spectroscopy Equipment and Accessories - Global ... offering. This report analyzes ... Accessories in US$ Thousands by the following ... Spectrometers, NMR-EPR Spectrometers, Near Infrared (NIR) Spectrometers, ...
(Date:8/19/2014)... 19, 2014 In November 2012, the European ... Evaluation Report (PBRER) in a new PSUR – responding to ... benefit-risk profile of a drug. Adopted in many regions, the ... Present a comprehensive and critical analysis of new or ... Highlight any new evidence of the potential benefits of ...
(Date:8/19/2014)... - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ... Oral Amphotericin B (Oral Amp B) drug candidate ... ImmuneCarta®, the immune monitoring business unit of Caprion, ... Amp B in reactivating latent HIV viral reservoirs ... with antiretroviral therapy. Memory cells, ...
Breaking Biology Technology:As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3
... ability to drive clients, success in managed care, ... Group, a,full-service managed market agency focused on securing ... of Dan Renick, RPh,as Managing Partner. Renick will ... biotech clients, including GlaxoSmithKline,sanofi-aventis, and Forest Laboratories., ...
... Abbott will present,at the Goldman Sachs Twenty-Ninth ... Thomas C. Freyman, executive vice president,finance and chief ... at 3:20 p.m. Central time., A live ... through,Abbott,s Investor Relations Web site at http://www.abbottinvestor.com ...
... China, May 28 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc.,(Nasdaq: ... focused on researching,developing, manufacturing and marketing biopharmaceutical ... Chief Operating Officer, and,Kevin Teo, Chief Financial ... Annual Global Healthcare Conference in Dana Point, ...
Cached Biology Technology:Dan Renick, RPh, Joins The Hobart Group as Managing Partner 2
(Date:8/20/2014)... In leaves, photosystem 1 (PS1) absorbs light and ... of carbon dioxide to biomass. Photovoltaic devices, mostly ... light but produce electricity. One approach for the ... replacing the semi-conductor with the isolated membrane protein ... isolates a highly stable PS1 from thermophilic cyanobacteria ...
(Date:8/19/2014)... China,s increasing caesarean section rate, suggests a new commentary ... Journal of Obstetrics and Gynaecology (BJOG) . , China ... the world. Of 16 million babies born in 2010, ... is not known, the current Chinese language literature on ... from 36% to 58%. However, before the 1980s, the ...
(Date:8/19/2014)... Wind and ... amount of electricity is to be produced with renewable energy ... stored during productive periods so that these fluctuations can be ... for the purpose. Science and industry are therefore working on ... that used to be too expensive or unsophisticated to be ...
Breaking Biology News(10 mins):A semi-artificial leaf faster than 'natural' photosynthesis 2Is China's 50 percent cesarean section delivery rate too high? 2Is China's 50 percent cesarean section delivery rate too high? 3Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3
... (March 28, 2011)Understanding that angioplastya medical treatment used by ... and chest to improve blood flowis safe may encourage ... for individuals with multiple sclerosis, say researchers at the ... Chicago, Ill. "Angioplastythe nonsurgical procedure of threading a ...
... March 28, 2011 University of Utah scientists used ... and toadfish inner-ear cells send signals to the brain. ... and lead to devices to restore vision, maintain balance ... to talk to the brain with optical infrared pulses ...
... JOLLA, CA Over the last years, two teams of ... model of how a powerful DNA repair complex works. Now, ... molecular motor inside the complex functions findings they say ... to cystic fibrosis. In a paper published in an ...
Cached Biology News:Interventional radiologists advance MS research: Vein-opening treatment safe 2Interventional radiologists advance MS research: Vein-opening treatment safe 3Interventional radiologists advance MS research: Vein-opening treatment safe 4Will we hear the light? 2Will we hear the light? 3Will we hear the light? 4Will we hear the light? 5Structure of DNA repair complex reveals workings of powerful cell motor 2Structure of DNA repair complex reveals workings of powerful cell motor 3Structure of DNA repair complex reveals workings of powerful cell motor 4
... These handy dispensers save space and ... and other garb. They are the ... parts used in labs, processing and ... charges and the particles they attract. ...
... These handy dispensers save space and ... and other garb. They are the ... parts used in labs, processing and ... charges and the particles they attract. ...
... that it uses a deep-UV deuterium bulb, which ... with a shutter (controlled via a TTL signal ... Source produces a powerful, stable output from 215-400 ... source are available, providing a wavelength range of ...
... and mitochondrial membrane potential. The mitochondrial permeability ... the initiation of cellular apoptosis. This process ... the electrochemical gradient across the mitochondrial membrane, ... membrane potential (YD). Loss of mitochondrial YD ...
Biology Products: